🇺🇸 FDA
Patent

US 11345904

Targeted therapeutic lysosomal enzyme fusion proteins, associated formulations and uses thereof

granted A61KA61K38/43A61K38/47

Quick answer

US patent 11345904 (Targeted therapeutic lysosomal enzyme fusion proteins, associated formulations and uses thereof) held by BIOMARIN PHARMACEUTICAL INC. expires Mon May 26 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
BIOMARIN PHARMACEUTICAL INC.
Grant date
Tue May 31 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon May 26 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
20
CPC classes
A61K, A61K38/43, A61K38/47, A61K47/26, A61K47/65